SRR5088842
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.600
- XENOBIOTIC_METABOLISM+0.600
- COAGULATION+0.500
- FATTY_ACID_METABOLISM+0.500
- ADIPOGENESIS+0.400
- ESTROGEN_RESPONSE_LATE+0.400
- KRAS_SIGNALING_DN+0.400
- MYOGENESIS+0.400
- PANCREAS_BETA_CELLS+0.400
- PEROXISOME+0.400
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- PI3K_AKT_MTOR_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.300
- PROTEIN_SECRETION-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2771617 | — | — | 0.802 |
| 2 | SRR5088897 | — | — | 0.801 |
| 3 | SRR5088896 | — | — | 0.801 |
| 4 | TCGA-OL-A5D6-01A-21R-A27Q-07 | — | F | 0.800 |
| 5 | SRR15030843 | — | — | 0.790 |
| 6 | TCGA-21-5784-01A-01R-1635-07 | — | cohortSQ1 | 0.781 |
| 7 | AUR-AFE9-TTM4-A-1-1-R-A742-41 | — | C | 0.776 |
| 8 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.773 |
| 9 | 1652b0a3-dc1d-4490-9632-07673713deb1 | — | — | 0.771 |
| 10 | 20050118.TNBC | — | F | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.600 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.600 | Inavolisib | — uncovered |
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.500 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| PEROXISOME | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |